Anjin Group, Inc.

Cockeysville, MD 21030

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $567K
First Award Date 02/01/05
Most Recent Award Date 09/01/08

Key Personnel

Last Name Name Awards Contact
Vanderspek Johanna Catharina Vanderspek 4

4 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/01/08 - 02/28/10

DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial cell monolayers. The goals of this Phase I proposal are to evaluate two, in vivo models of v...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/01/08 - 08/28/09

DESCRIPTION (provided by applicant): A number of protein fusion toxins, composed of the diphtheria toxin (DT) toxophore and a targeting ligand, have been assembled and tested in Phase I clinical trials for the treatment of leukemias. To date, the only FDA approved protein fusion toxin is ONTAK. ONTAK is a DT, interleukin-2 receptor-targeted fusi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/06 - 08/30/07

DESCRIPTION (provided by applicant): Sweeney et al. (1998) originally reported the construction of DAB389IL-7, a fusion protein based on diphtheria toxin (DT), and proposed that this fusion protein could be employed as a therapeutic agent for hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/05 - 02/01/06

DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of refractory cutaneous T cell lymphoma. The fusi...